23 May 2013
Keywords: ph, iii, trial, acorda, ms, drug, completes
Article | 13 March 2006
USA-based Acorda Therapeutics has completed enrollment in a Phase III clinical trial of Fampridine-SR (4-aminopyridine) in multiple
sclerosis. The study, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 June 2006
© 2013 thepharmaletter.com